UNSPSC 51263000: Adrenergic blocking agent piperazines

This classification denotes adrenergic blocking agents made from organic compounds composed of a six-membered ring containing two nitrogen atoms at opposite positions (hexa-hydro-pyrazine(s)).

UNSPSC 51263000 Adrenergic blocking agent piperazines is a Class code that shows a significant mismatch between its nominal pharmaceutical scope and actual recent state and local procurement activity. The two most recent opportunities tagged under this code do not involve adrenergic blocking agents or piperazines at all. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding, with quarterly deliveries to the county community health building and a two-year initial term with optional one-year renewal. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels.

The issuing-body mix spans state health agencies and county public health departments. Geographic activity appears concentrated in Florida and Texas based on the recent record. The Seminole County opportunity requires electronic bid submission through the county e-Procurement Portal with unit pricing for each line item, drug-free workplace certification, E-Verify compliance, and standard insurance coverages; the contract includes a three-month probationary period permitting termination with or without cause and potential FEMA funding with accompanying federal compliance obligations. The Texas RFI represents preliminary market intelligence gathering rather than a formal competitive solicitation, designed to inform the state's future contracting strategy for direct manufacturer prescription fulfillment before issuing a formal RFP with established financial and temporal parameters. The code appears to show little relevant recent activity for adrenergic blocking agents specifically, suggesting either a classification error or a very narrow or inactive procurement lane for this specific pharmaceutical category at the state and local level.